Time to treatment and cost of thrombolysis: A multicenter comparison of tPA and rPA

Journal of Thrombosis and Thrombolysis

Volumn 9, Issue 3, 2000, Pages 303-308

  Seyedroudbari, Ali ^a   Kessler, E Richard ^b   Mooss, Aryan N ^a   Wurdeman, Richard L ^a   Bala, Mohan ^c   Hilleman, Daniel E ^a,d  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Medical Center of Bowling Green   (United States)

^c CENTOCOR INC   (United States)

^d CREIGHTON UNIVERSITY   (United States)

Author keywords

Alteplase; Intravenous infection; Myocardial infarction; Reteplase; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; RETEPLASE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TIME;

EID: 0034072763     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018797411812     Document Type: Article

References (14)

1. White H, Van de Werf F. Thrombolysis for acute myocardial infarction. Circulation 1998;97:1632-1646.
2. Smalling R. A fresh look at the molecular pharmacology of plasminogen activators: From theory to test tube to clinical outcomes. Am J Health Syst Pharm 1997;54:517-522.
3. Gonzalez E, Jones L, Ornato J. Hospital days and problems with thrombolytic administration in patients receiving thrombolytic therapy: A multicenter prospective assessment. Am Emerg Med 1992;21:1215-1221.
4. The GUSTO-III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118-1123.
5. FTT Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311-322.
6. Kline E, Smith O, Martin J. In-hospital treatment delays in patients treated with thrombolytic therapy: A report of the GUSTO time-to-treat substudy. Circulation 1992;86:702.
7. Ryan T, Anderson J, Antman L. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Proactive Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;27:737-750.
8. Rogers W, Bowlby L, Nisha C. Treatment of myocardial infarction in the United States (1990-1995). Circulation 1994;90:2103-2114.
9. Sharkey S, Brunette D, Ruiz E. An analysis of time delays preceding thrombolysis for acute myocardial infarction. JAMA 1989;262:3171-3174.
10. Tiefenbrunn AJ, Chandra NC, French WJ, et al. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction. JACC 1998;31(6):1240-1245.
11. Kirchbaum DW, Grabavoy O, Finley RC, Harnid I. Use of alteplase for myocardial infarction in two community hospitals. Am J Hosp Pharm 1990;47:1535-1540.
12. Newby KL, Rutsch WR, Califf RM, et al. Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996;27:1645-1646.
13. Kereiakes DJ, Weaver DW, Anderson JL, et al. Time delays in the diagnosis and treatment of acute myocardial infarction: A tale of eight cities. Am Heart J 1990;120: 773-780.
14. Lambrew CT, Bowlby LJ, Rogers WJ, Chandra NC, Weaver WD, for the Time to Thrombolysis substudy of the National Registry of Myocardial Infarction-1. Factors influencing the time to thrombolysis in acute myocardial infarction. Arch Intern Med 1997;157:2577-2582.